Evidence map›Paper›PMID 33517886›Full record

ArticleBMC medicine2021

Development and validation of a novel circular RNA as an independent prognostic factor in acute myeloid leukemia.

Jinghan Wang, Jiajia Pan, Shujuan Huang, Fenglin Li, Jiansong Huang, Xia Li, Qing Ling, Wenle Ye, Yungui Wang, Wenjuan Yu and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMC medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 3 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Cancers · 2023
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Jinghan Wang *Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, No. 79 Qingchun Road, Hangzhou, 310003, Zhejiang, People's Republic of China.
Jiajia Pan *Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Hangzhou, Zhejiang, People's Republic of China.
Shujuan HuangKey Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Hangzhou, Zhejiang, People's Republic of China.
Fenglin LiKey Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Hangzhou, Zhejiang, People's Republic of China.
Jiansong HuangKey Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Hangzhou, Zhejiang, People's Republic of China.
Xia LiKey Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Hangzhou, Zhejiang, People's Republic of China.
Qing LingKey Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Hangzhou, Zhejiang, People's Republic of China.
Wenle YeKey Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Hangzhou, Zhejiang, People's Republic of China.
Yungui WangKey Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Hangzhou, Zhejiang, People's Republic of China.
Wenjuan YuDepartment of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, No. 79 Qingchun Road, Hangzhou, 310003, Zhejiang, People's Republic of China.
Jie JinDepartment of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, No. 79 Qingchun Road, Hangzhou, 310003, Zhejiang, People's Republic of China. jiej0503@zju.edu.cn.
Zhejiang University · CNFirst Affiliated Hospital Zhejiang University · CN

Funding

Natural Science Foundation of Zhejiang Province LY19H080009Natural Science Foundation of Zhejiang Province LY20H080008
6 · The paper itself

Abstract

backgroundAlthough there are many clinical and molecular biomarkers in acute myeloid leukemia (AML), the novel and reliable biomarkers are still required to predict the overall survival at the time of disease diagnosis.

methodsIn order to identify independent predictors, we firstly selected 60 cytogenetically normal AML (CN-AML) patients using the propensity score analysis to balance the confounders and performed circular RNA (circRNA) sequencing. Next, one outcome related to circRNA was selected and validated in the independent cohort of 218 CN-AML patients. We then constructed circRNA-miRNA-mRNA regulated network and performed cellular metabolomic analysis to decipher the underlying biological insights.

resultsWe identified 308 circRNAs as independent candidate predictors of overall survival. Hsa_circ_0075451 expression was validated as an independent predictor with a weak predictive ability for overall survival. The regulated network of this circular RNA indicated 84 hub genes that appear to be regulated by 10 miRNAs sponged by hsa_circ_0075451. The regulatory axis of hsa_circ_0075451 -| miR-330-5p/miR-326 -| PRDM16 was validated by the dual luciferase report assay, fluorescence in situ hybridization, and ShRNA interference assay.

conclusionsOur data demonstrates that hsa_circ_0075451 expression may independently contribute to the poor prognosis of AML and present a novel therapeutic target.

Indexed as

Biomarkers, TumorGene Expression Regulation, NeoplasticHumansIn Situ Hybridization, FluorescenceLeukemia, Myeloid, AcuteMaleMicroRNAsPrognosisRNARNA, CircularRNA, MessengerSequence Analysis, RNABiomarkers, TumorMicroRNAsMIRN330 microRNA, humanRNARNA, CircularRNA, MessengerAcute myeloid leukemiaCircular RNAsPrognosisRNA sequencing

Identifiers

PMID33517886
PMCPMC7849103
OpenAlexW3126719615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.